Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rainmed Medical's total equity for the quarter that ended in Dec. 2025 was HK$395.48 Mil.
This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.
The historical data trend for Rainmed Medical's Total Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rainmed Medical (HKSE:02297) has a Total Equity of HK$395.48 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Rainmed Medical and its competitors.
Is Rainmed Medical's Total Equity too high?
Rainmed Medical's current Total Equity is HK$395.48 Mil. Overall, Rainmed Medical has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rainmed Medical's Total Equity compare to ABT and SYK?
Rainmed Medical's Total Equity of HK$395.48 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Rainmed Medical and its competitors. Rainmed Medical's current Total Equity is HK$395.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rainmed Medical stock overvalued right now?
Based on GuruFocus' analysis, Rainmed Medical (HKSE:02297) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.08, compared to a current price of HK$0.22 — trading 175% above its estimated fair value. The current Total Equity is HK$395.48 Mil. Rainmed Medical's overall GF Score™ is 49/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Rainmed Medical (HKSE:02297), the current Total Equity is HK$395.48 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rainmed Medical (HKSE:02297) Overvalued in 2026?
Based on GuruFocus' analysis, Rainmed Medical stock appears to be overvalued.
The current stock price of HK$0.22 is trading 175% above its estimated GF Value™ of HK$0.08.
GuruFocus considers Rainmed Medical to be Significantly Overvalued.
Key valuation signals for HKSE:02297:
Total Equity: HK$395.48 Mil
GF Value™: HK$0.08 vs. price of HK$0.22 (175% above fair value)
No single metric tells the full story. See the HKSE:02297 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rainmed Medical Ltd is focused on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microcirculatory resistance systems. The company's core products, the caFFR system and the caIMR system, are medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). It operates in China and Other countries.
49GF Score
Get the complete analysis for HKSE:02297
Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02297 has been successfully added to your 
